Trisol Medical
Yokneam, Israel· Est.
Trisol Medical creates a minimally invasive, nitinol‑based transcatheter valve to treat severe tricuspid regurgitation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Trisol Medical creates a minimally invasive, nitinol‑based transcatheter valve to treat severe tricuspid regurgitation.
Cardiovascular
Technology Platform
A nitinol self‑expanding frame with a dome‑shaped leaflet enabling fully percutaneous transcatheter tricuspid valve replacement while preserving right‑ventricular function.
Opportunities
A large, underserved patient population with severe tricuspid regurgitation and growing demand for minimally invasive valve therapies.
Risk Factors
Regulatory approval uncertainty, clinical trial outcomes, and competition from established device manufacturers.
Competitive Landscape
Competes with early‑stage TTVR devices from Edwards, Medtronic, and Abbott; differentiates through a nitinol‑based, low‑profile design promising better anchoring and fewer conduction issues.